Herbal Approaches to Herpes Zoster Management: A Review of Eucalyptus Oil and Ashwagandha as Topical Therapeutic Agents

Vivek Gautam; Ayush Agrawal; Pritam Kushwaha; Khalasi Krishna Dipakbhai; Anshul Chaubey

Herbal Approaches to Herpes Zoster Management: A Review of Eucalyptus Oil and Ashwagandha as Topical Therapeutic Agents

Author(s)	Mr. Vivek Gautam, Mr. Ayush Agrawal, Mr. Pritam Kushwaha, Miss. Khalasi Krishna Dipakbhai, Mr. Anshul Chaubey
Country	India
Abstract	Herpes zoster (HZ), caused by reactivation of latent varicella-zoster virus (VZV) in dorsal root or cranial nerve ganglia, remains a major cause of dermatomal pain and post-herpetic neuralgia (PHN), particularly among older and immunocompromised individuals. Standard management relies on systemic nucleoside analogues (acyclovir, valacyclovir, famciclovir) initiated within 72 hours of rash onset, together with analgesics and, in selected cases, corticosteroids; however, drug resistance, side effects, and incomplete prevention of PHN continue to drive interest in adjunctive and complementary approaches. This narrative review synthesizes the preclinical and mechanistic evidence supporting two botanicals with topical therapeutic potential in HZ: eucalyptus oil (Eucalyptus spp., principally standardized to its major monoterpene 1,8-cineole) and ashwagandha (Withaniasomnifera). Eucalyptus oil and its monoterpene constituents (1,8-cineole, α-pinene, γ-terpinene, α-terpineol) have demonstrated direct virucidal activity against herpes simplex virus (HSV-1 and HSV-2) in cell culture, acting principally at the stage of viral adsorption and entry, alongside anti-inflammatory and analgesic actions relevant to zoster-associated pain. Ashwagandha, rich in withanolides such as withaferin A and withanolide A, exhibits immunomodulatory, antiviral, anti-inflammatory, and wound-healing properties in preclinical models, including suppression of NF-κB/MAPK signaling and pro-inflammatory cytokines in human keratinocytes. Taken together, the mechanistic profiles of both agents are pharmacologically compatible with the goals of HZ management—viral suppression, inflammation control, analgesia, and lesion healing—supporting a biological rationale for their adjunctive topical use. However, no dedicated clinical trials of eucalyptus oil, ashwagandha, or their combination specifically in herpes zoster were identified in the literature reviewed; the evidence base rests on HSV surrogate models, in vitro/animal anti-inflammatory studies, and dermatological safety data. This review therefore also identifies critical gaps and outlines a research agenda—including VZV-specific antiviral testing, standardized topical formulation development, and controlled clinical trials—needed before these agents can be recommended as evidence-based adjuncts to standard HZ care.
Keywords	Herpes zoster; varicella-zoster virus; eucalyptus oil; 1,8-cineole; Withaniasomnifera; ashwagandha; withanolides; topical phytotherapy; complementary medicine
Field	Medical / Pharmacy
Published In	Volume 17, Issue 3, July-September 2026
Published On	2026-08-18

View / Download PDF File

About IJSAT Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics	Join as a Reviewer Editors & Reviewers Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us	Message on WhatsApp	+91-9687-182-185	editor@ijsat.org

International Journal on Science and Technology

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Herbal Approaches to Herpes Zoster Management: A Review of Eucalyptus Oil and Ashwagandha as Topical Therapeutic Agents

Share this